CHEK2 Antilichaam - N-terminalgebied: FITC (ARP30290_P050-FITC)

Checkpoint kinase 2

CDS1, CHK2, LFS2, RAD53, hCds1, HuCds1, PP1425

11200

O96017-12

NP_665861

Human

The immunogen is a synthetic peptide directed towards the N terminal region of human CHEK2

In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. CHEK2 is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, CHEK2 is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in its gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in its gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases.In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.

SRPK1; PPP2CA; PLK1; CHEK2; PRKDC; ATM; POLR2L; RCHY1; VHL; UBC; NR4A1; ELAVL1; CDC25A; ARHGAP1; PER3; CDC25C; CUL1; CUL4A; KPNA2; APP; STRAP; TP53; BRCA1; RB1; DAPK3; UBR5; PML; MDM2; BRCA2; KAT2B; LATS2; PSME3; TRIM28; RNF8; STAT1; PPP2R5E; PPP2R5D; PPP

FITC: Fluorescein Isothiocyanate

Polyclonal Antibody

IHC, WB

Affinity Purified

CHEK2 is supported by BioGPS gene expression data to be expressed in Jurkat

0.5 mg/ml

Human: 100%

Liquid. Purified antibody supplied in 1x PBS buffer.

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.

58kDa

Kobayashi, A., (2006) Histol. Histopathol. 21 (4), 373-382

Wet Ice

514

CHEK2

CHEK2

Rabbit

Serine/threonine-protein kinase Chk2

NM_145862

MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSS